全球過繼性細胞療法市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球過繼性細胞療法市場預計將從2025年的130.9億美元成長至2034年的370.7億美元，2026年至2034年的複合年成長率（CAGR）為12.26%。隨著製藥和生物技術公司不斷推動利用免疫細胞靶向特定疾病的個人化細胞療法的研發，該市場正在蓬勃發展。過繼性細胞療法是指在將免疫細胞輸注給患者之前，先進行採集、改造或擴增，尤其在腫瘤治療領域備受關注。 CAR-T細胞療法已展現出基因改造免疫細胞在某些血液癌症治療中的潛力，這推動了對其他細胞療法的進一步研究。對細胞免疫療法的持續投資正在支持製藥公司、生技公司、醫院和研究機構的研發工作。

研究日益聚焦於拓展過繼性細胞療法的應用範圍，使其超越既定適應症。科學家正在探索T細胞受體療法、腫瘤浸潤淋巴細胞、自然殺手細胞以及新一代基因修飾免疫細胞。研發人員也在努力提高細胞的持久性、標靶特異性、生產一致性以及治療的可及性。基因編輯和細胞工程技術的進步為開發更先進的療法開闢了新的途徑。然而，生產複雜性、治療成本、患者合格和臨床管理要求仍然是商業化過程中需要考慮的關鍵因素。

未來前景取決於臨床開發、生產製造創新、監管進步以及應對當前細胞療法相關挑戰的能力。自動化生產系統和冷凍保存技術的改進有助於提高生產效率和一致性。一旦技術和臨床挑戰得到解決，對「現成」或異體細胞療法的研究也有助於擴大患者的可及性。針對固體癌和其他疾病的治療方法的開發有望顯著擴大市場。研究人員、醫院和生物技術公司之間的持續合作有望推動細胞免疫療法的創新。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭動態以及主要參與者所採取的策略。

市場預測：基於數據對指定預測期內市場規模和成長模式的展望。本部分結合歷史趨勢、當前市場狀況和定量分析，揭示未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球過繼性細胞療法市場：按類型分類

• 市場分析、洞察與預測
• CAR-T
• TCR-T
• NK
• TIL

第5章：全球過繼性細胞療法市場：依應用領域分類

• 市場分析、洞察與預測
• 淋巴瘤
• 白血病
• 其他

第6章：全球過繼性細胞療法市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院
• 癌症治療中心

第7章 全球過繼性細胞療法市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Novartis AG
  • Gilead Sciences Inc
  • Castle Creek Biosciences Inc
  • Lineage Cell Therapeutics Inc
  • Transgene SA
  • Cellectis
  • ImmunityBio Inc
  • Bluebird Bio Inc
  • Arcellx Inc
  • Sana Biotechnology Inc
  • Biodesix Inc
  • Laurus Labs

The global adoptive cell therapy market size is expected to reach USD 37.07 Billion in 2034 from USD 13.09 Billion in 2025, growing at a CAGR of 12.26% during 2026-2034.This market is developing as pharmaceutical and biotechnology companies advance personalized cellular therapies designed to use immune cells to target specific diseases. Adoptive cell therapy involves collecting, modifying or expanding, and administering immune cells to patients, with applications particularly associated with oncology. CAR-T cell therapy has demonstrated the potential of engineered immune cells in selected blood cancers, encouraging further research into other cell-based approaches. Continued investment in cellular immunotherapy is supporting development across pharmaceutical companies, biotechnology firms, hospitals, and research institutions.

Research is increasingly focused on expanding adoptive cell therapy beyond established applications. Scientists are investigating T-cell receptor therapies, tumor-infiltrating lymphocytes, natural killer cells, and next-generation engineered immune cells. Developers are also working to improve cell persistence, target specificity, manufacturing consistency, and treatment accessibility. Advances in gene editing and cell engineering are providing additional tools for developing more sophisticated therapies. However, manufacturing complexity, treatment costs, patient eligibility, and clinical-management requirements remain important considerations for commercialization.

Future prospects depend on clinical development, manufacturing innovation, regulatory progress, and the ability to address limitations associated with current cell therapies. Automated manufacturing systems and improved cryopreservation could help increase production efficiency and consistency. Research into off-the-shelf or allogeneic cell therapies may also support broader access if technical and clinical challenges are addressed. The development of therapies targeting solid tumors and additional diseases could expand the market considerably. Continued collaboration between researchers, hospitals, and biotechnology companies is expected to drive innovation in cellular immunotherapy.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• CAR-T
• TCR-T
• NK
• TIL

By Application

• Lymphoma
• Leukemia
• Others

By End User

• Hospitals
• Cancer Treatment Centers

COMPANIES PROFILED

• Novartis AG, Gilead Sciences Inc., Castle Creek Biosciences Inc., Lineage Cell Therapeutics Inc., Transgene SA, Cellectis, ImmunityBio Inc., bluebird bio Inc., Arcellx Inc., Sana Biotechnology Inc., Biodesix Inc., Laurus Labs

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ADOPTIVE CELL THERAPY MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. CAR-T Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. TCR-T Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. NK Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. TIL Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ADOPTIVE CELL THERAPY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ADOPTIVE CELL THERAPY MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Cancer Treatment Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ADOPTIVE CELL THERAPY MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Application
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Application
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Spain
  • 7.3.9 Russia
  • 7.3.10 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Application
  • 7.4.3 By End User
  • 7.4.4 China
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 India
  • 7.4.8 Australia
  • 7.4.9 South East Asia
  • 7.4.10 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Application
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Application
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ADOPTIVE CELL THERAPY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Novartis AG
  • 9.2.2 Gilead Sciences Inc
  • 9.2.3 Castle Creek Biosciences Inc
  • 9.2.4 Lineage Cell Therapeutics Inc
  • 9.2.5 Transgene SA
  • 9.2.6 Cellectis
  • 9.2.7 ImmunityBio Inc
  • 9.2.8 Bluebird Bio Inc
  • 9.2.9 Arcellx Inc
  • 9.2.10 Sana Biotechnology Inc
  • 9.2.11 Biodesix Inc
  • 9.2.12 Laurus Labs